Skip to main content
Premium Trial:

Request an Annual Quote

Whitehead-Led Team Says Animal Clones Would Likely Be Abnormal

NEW YORK, Sept. 10 - About four percent of expressed genes in cloned mice are abnormal, according to research done at the Whitehead Institute.

Though they are not necessary evident at the phenotypic level via clinical examination, these abnormalities could lead to severe health problems, the researchers report.

 

"Recent studies showing premature death, pneumonia, liver failure, and obesity in aging cloned mice could be a consequence of these gene-expression abnormalities," the authors write in a paper slated to appear this week in the Proceedings of the National Academies of Science.

 

Embryonic stem cells used to make whole animals "would likely produce organisms that are abnormal, since many of the abnormally expressed genes have defined roles in fetal development," concluded Rudolf Jaenisch, the study's principal investigator.

 

Jaenisch and colleagues used Affymetrix gene arrays to screen 10,000 genes for abnormalities in the placentas and livers of cloned mice. The researchers said cloned animals should be examined via molecular tissue analyses as well as clinical examinations.

 

Participating in the study were researchers from the Whitehead Institute for Biomedical Research, the John A. Burns School of Medicine at the University of Hawaii, the Dana-Farber Cancer Institute, and Harvard Medical School.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more